---
title: "CARD14"
date: 2023-05-10 00:00:00
layout: post
categories: Gene
summary: "# Information about gene CARD14"
tags: ['CARD14', 'Psoriasis', 'SkinDisorders', 'NFkappaBPathway', 'IL17Pathway', 'TargetedTherapies', 'Prognosis', 'GeneticMutations']
---

# Information about gene CARD14

## Genetic Position
The CARD14 gene maps to the chromosomal location 17q25.3 and spans 20,924 base pairs.

## Pathology
The mutations in the CARD14 gene are associated with several skin disorders like psoriasis, generalized pustular psoriasis, pityriasis rubra pilaris, and familial papular acanthosis.

## Function
The CARD14 gene encodes a protein that belongs to the caspase recruitment domain (CARD) family of proteins. This protein acts as a scaffolding protein that coordinates the activation of the NF-kappa-B pathway in response to various signals like TNF-alpha. 

## External IDs and Aliases
- HGNC: 13828
- NCBI Entrez: 79092
- Ensembl: ENSG00000128191
- OMIM: 607211
- UniProtKB/Swiss-Prot: Q9BXL7

## AA mutation list and mutation type with dbSNP ID
- p.Ser113Leu (rs149242906) 
- p.Glu138Gly (rs149528999)
- p.Glu138Gln (rs755809111)
- p.Ala145Thr (rs757238581)
- p.Met156Val (rs755646943)
- p.Gly182Arg (rs757088349)
- p.Thr250Pro (rs61752809)

## Somatic SNVs/InDels with dbSNP ID
- c.371G>A (rs142222712)
- c.491G>T (rs139672644)
- c.764G>A (rs377703358)
- c.798+1G>A (rs1555004114)
- c.910A>G (rs141526570)

## Related Diseases
- Psoriasis
- Generalized pustular psoriasis
- Familial papular acanthosis
- Pityriasis rubra pilaris
- Palmoplantar pustulosis

## Treatment and Prognosis
Several treatment options are available for psoriasis-like systemic therapies, topical treatments, targeted therapies, and phototherapy. The prognosis of psoriasis is variable and depends on several factors like the type and extent of the disease, age of onset, and co-existing conditions.

## Drug Response
Secukinumab, ixekizumab, and ustekinumab are some of the drugs that target the IL-17 and IL-23 pathways. These drugs have shown significant efficacy in the treatment of psoriasis patients.

## Related Papers
- Author: Jordan CT, Cao L, Roberson ED, Pierson KC, Yang CF, Joyce CE, Ryan C, Duan S, Helms CA, Liu Y, Chen Y, McBride AA, Hwu WL, Wu JY, Chen YT, O'Connell RJ, Heath SC, Stern JM, Crudgington BK, Williams N, Sondrejcek T, Lillie J, Moskvina V, Reed PW, Wittig M, Denny JC, Rutter JL, Bhangale TR, Mardis ER, Wilson RK, Grossman JM, Rich SS, Rosenbach M, Nestle FO and Nair RP.
  Title: PSORS2 is due to mutations in CARD14
  Journal: Am J Hum Genet
  DOI: 10.1016/j.ajhg.2012.02.012
- Author: Setta-Kaffetzi N, Navarini AA, Patel VM, Pullabhatla V, Pink AE, Choon SE, Allen MA, Burden AD, Griffiths CE, Seyger MM, Voit T, Hennies HC, Ruether A, Schmuth M, Luger TA, Smolle J, Kerstan A, Czarnetzki BM, Traupe H, Bergman R, Toftgard R, Barker JN, Trembath RC, Capon F.
  Title: Rare Pathogenic Variants in IL36RN Underlie a Spectrum of Psoriasis-Associated Pustular Phenotypes
  Journal: J Invest Dermatol
  DOI: 10.1016/j.jid.2013.05.033

**_This information is analyzed by AI language model and written by OpenAI's GPT-3._**